{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:44:47Z","timestamp":1785465887491,"version":"3.56.0"},"reference-count":67,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In contrast to major innovations in treating severe hemophilia, the treatment of severe von Willebrand disease (VWD) remains limited to intravenous infusion of von Willebrand factor (VWF) concentrates. To date, no gene therapy\u2013based approaches for the treatment of VWD have been developed, largely owing to the disease\u2019s heterogeneous mutational landscape and the challenge of specifically targeting VWF production in endothelial cells. In this study, we developed a novel gene therapy strategy for patients with VWD caused by heterozygous dominant-negative VWF variants. Our strategy permanently inactivates VWF variants by selectively disrupting the pathogenic allele\u2019s open reading frame via the introduction of indels by Cas9. To circumvent the challenge of designing variant-specific strategies, we targeted the common single nucleotide polymorphism (SNP) rs1800378 in VWF. We used endothelial colony-forming cells (ECFCs) from patients with VWD2A and VWD2B with heterozygous p.C1190R and p.R1306W variants, respectively, to demonstrate ex vivo proof of principle. Using next-generation sequencing analysis, we show efficient and allele-selective knockout of VWF, while maintaining VWF expression of the nontargeted allele. Variant mapping mass spectrometry that discriminates between wild-type and variant VWF proteoforms confirmed selective reduction of variant allele expression, which was accompanied by reversal of cellular disease phenotypes in ECFCs. This study shows the feasibility of a novel gene editing strategy for VWD that, by virtue of its targeting of a common SNP, can be broadly applicable and can be used to design treatments for VWD without being constrained by the disease-causing variant, pathogenic mechanism, or VWD subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018760","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:31:37Z","timestamp":1766086297000},"page":"1429-1443","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Allele-selective disruption of pathogenic\n                    <i>VWF<\/i>\n                    variants in type 2 von Willebrand disease using CRISPR\/Cas9"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9493-6072","authenticated-orcid":false,"given":"Isabel","family":"B\u00e4r","sequence":"first","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-9939","authenticated-orcid":false,"given":"Stijn A.","family":"Groten","sequence":"additional","affiliation":[{"name":"2Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-5672","authenticated-orcid":false,"given":"Alastair","family":"Barraclough","sequence":"additional","affiliation":[{"name":"2Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-8028","authenticated-orcid":false,"given":"Petra E.","family":"B\u00fcrgisser","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-1496","authenticated-orcid":false,"given":"Calvin","family":"van Kwawegen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-3429","authenticated-orcid":false,"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[{"name":"3H\u00e9mostase, Inflammation, Thrombose U1176, INSERM, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0248-4710","authenticated-orcid":false,"given":"Iris","family":"van Moort","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-5759","authenticated-orcid":false,"given":"Jeroen C. J.","family":"Eikenboom","sequence":"additional","affiliation":[{"name":"4Einthoven Laboratory for Vascular and Regenerative Medicine, Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1371","authenticated-orcid":false,"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-2621","authenticated-orcid":false,"given":"Jan","family":"Voorberg","sequence":"additional","affiliation":[{"name":"2Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"},{"name":"5Experimental Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-5496","authenticated-orcid":false,"given":"Maartje","family":"van den Biggelaar","sequence":"additional","affiliation":[{"name":"2Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-9689","authenticated-orcid":false,"given":"Ruben","family":"Bierings","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"21","key":"2026030916263022800_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2026030916263022800_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41572-024-00536-8","article-title":"von Willebrand disease","volume":"10","author":"Seidizadeh","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"13","key":"2026030916263022800_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2026030916263022800_bib4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2026030916263022800_bib5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood.2023021915","article-title":"Novel functions for von Willebrand factor","volume":"144","author":"Atiq","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026030916263022800_bib6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2026030916263022800_bib7","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1242\/jcs.208033","article-title":"Weibel-Palade bodies at a glance","volume":"130","author":"McCormack","year":"2017","journal-title":"J Cell Sci"},{"issue":"22","key":"2026030916263022800_bib8","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1111\/febs.16421","article-title":"Dispatch and delivery at the ER\u2013Golgi interface: how endothelial cells tune their hemostatic response","volume":"289","author":"Kat","year":"2022","journal-title":"FEBS J"},{"issue":"23","key":"2026030916263022800_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.23.1.101","article-title":"New cytoplasmic components in areal endothelia","volume":"1","author":"Weibel","year":"1964","journal-title":"J Cell Biol"},{"issue":"5","key":"2026030916263022800_bib10","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jtha.2024.01.015","article-title":"A new look at an old body: molecular determinants of Weibel-Palade body composition and von Willebrand factor exocytosis","volume":"22","author":"Hordijk","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026030916263022800_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/hae.12254","article-title":"Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders","volume":"20","author":"Leissinger","year":"2014","journal-title":"Haemophilia"},{"issue":"4","key":"2026030916263022800_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026030916263022800_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest"},{"issue":"1","key":"2026030916263022800_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.14322","article-title":"Exocytosis of Weibel\u2013Palade bodies: how to unpack a vascular emergency kit","volume":"17","author":"Schillemans","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2026030916263022800_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"Von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"de Jong","year":"2017","journal-title":"Thromb Res"},{"issue":"12","key":"2026030916263022800_bib16","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41431-021-00959-x","article-title":"The LOVD3 platform: efficient genome-wide sharing of genetic variants","volume":"29","author":"Fokkema","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"2026030916263022800_bib17","doi-asserted-by":"crossref","first-page":"E718","DOI":"10.1097\/HS9.0000000000000718","article-title":"Importance of genotyping in von Willebrand disease to elucidate pathogenic mechanisms and variability in phenotype","volume":"6","author":"Atiq","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"2026030916263022800_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2010.03.003","article-title":"The genetic basis of von Willebrand disease","volume":"24","author":"Goodeve","year":"2010","journal-title":"Blood Rev"},{"issue":"11","key":"2026030916263022800_bib19","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.jtha.2024.06.026","article-title":"Unravelling the spectrum of von Willebrand factor variants in quantitative von Willebrand disease: results from a German cohort study","volume":"22","author":"Krahforst","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026030916263022800_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41525-023-00375-8","article-title":"Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases","volume":"8","author":"Seidizadeh","year":"2023","journal-title":"NPJ Genom Med"},{"key":"2026030916263022800_bib21","doi-asserted-by":"publisher","DOI":"10.1055\/a-2616-5161","article-title":"Landscape and spectrum of VWF variants in Type 2 von Willebrand disease: insights from a German patient cohort","author":"Yadegari","year":"5  2025","journal-title":"Thromb Haemost"},{"key":"2026030916263022800_bib22","doi-asserted-by":"crossref","first-page":"1620438","DOI":"10.3389\/fgeed.2025.1620438","article-title":"Rewriting the script: gene therapy and genome editing for von Willebrand disease","volume":"7","author":"Barraclough","year":"2025","journal-title":"Front Genome Ed"},{"issue":"8","key":"2026030916263022800_bib23","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jtha.2024.05.006","article-title":"Application of genetic testing for the diagnosis of von Willebrand disease","volume":"22","author":"Seidizadeh","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2026030916263022800_bib24","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/bloodadvances.2025016512","article-title":"2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease","volume":"9","author":"James","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026030916263022800_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"2026030916263022800_bib26","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood.2024026804","article-title":"DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis","volume":"145","author":"Laan","year":"2025","journal-title":"Blood"},{"issue":"suppl 3","key":"2026030916263022800_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/hae.14050","article-title":"von Willebrand disease: diagnosis and treatment, treatment of women, and genomic approach to diagnosis","volume":"27","author":"Laffan","year":"2021","journal-title":"Haemophilia"},{"issue":"17","key":"2026030916263022800_bib28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1182\/blood.2020008501","article-title":"von Willebrand disease: what does the future hold?","volume":"137","author":"Denis","year":"2021","journal-title":"Blood"},{"key":"2026030916263022800_bib29","doi-asserted-by":"crossref","first-page":"101131","DOI":"10.1016\/j.blre.2023.101131","article-title":"Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: a systematic review","volume":"62","author":"Eising","year":"2023","journal-title":"Blood Rev"},{"issue":"22","key":"2026030916263022800_bib30","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood.2024024209","article-title":"Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States","volume":"143","author":"Waldron","year":"2024","journal-title":"Blood"},{"key":"2026030916263022800_bib31","first-page":"17","article-title":"Cost\u2013consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context","volume":"7","author":"Schinco","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"suppl 1","key":"2026030916263022800_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-136241","article-title":"Cost-effectiveness of long-term prophylaxis versus on-demand treatment with von Willebrand factor concentrate in severe inherited von Willebrand disease","volume":"136","author":"Bhaskar","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2026030916263022800_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17474086.2025.2459259","article-title":"The future of siRNA-mediated approaches to treat von Willebrand disease","volume":"18","author":"Linthorst","year":"2025","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"2026030916263022800_bib34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/jth.14140","article-title":"Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor","volume":"16","author":"de Jong","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026030916263022800_bib35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1055\/s-0040-1715442","article-title":"Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-interfering RNA","volume":"120","author":"De Jong","year":"2020","journal-title":"Thromb Haemost"},{"issue":"2","key":"2026030916263022800_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/bloodadvances.2024014601","article-title":"Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs","volume":"9","author":"Linthorst","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026030916263022800_bib37","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/rth2.12242","article-title":"Alternative trafficking of Weibel-Palade body proteins in CRISPR\/Cas9-engineered von Willebrand factor-deficient blood outgrowth endothelial cells","volume":"3","author":"Schillemans","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2026030916263022800_bib38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2026030916263022800_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jtha.2024.10.023","article-title":"The severe von Willebrand disease variant p.M771V leads to impaired anterograde trafficking of von Willebrand factor in patient-derived and base-edited endothelial colony-forming cells","volume":"23","author":"B\u00e4r","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026030916263022800_bib40","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood-2005-03-1153","article-title":"A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B","volume":"106","author":"Hulstein","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2026030916263022800_bib41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jth.15598","article-title":"Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells","volume":"20","author":"Wohner","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026030916263022800_bib42","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1182\/bloodadvances.2023012499","article-title":"O-glycan determinants regulate VWF trafficking to Weibel-Palade bodies","volume":"8","author":"Karampini","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"2026030916263022800_bib43","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"pt 3","key":"2026030916263022800_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2818.2006.01706.x","article-title":"A guided tour into subcellular colocalization analysis in light microscopy","volume":"224","author":"Bolte","year":"2006","journal-title":"J Microsc"},{"issue":"6","key":"2026030916263022800_bib45","doi-asserted-by":"crossref","first-page":"e0278009","DOI":"10.1371\/journal.pone.0278009","article-title":"Automated segmentation and quantitative analysis of organelle morphology, localization and content using CellProfiler","volume":"18","author":"Laan","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"2026030916263022800_bib46","doi-asserted-by":"crossref","first-page":"e12595","DOI":"10.1002\/rth2.12595","article-title":"Quantitative 3D microscopy highlights altered von Willebrand factor \u03b1-granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms","volume":"5","author":"Swinkels","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"23","key":"2026030916263022800_bib47","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2009-07-226324","article-title":"A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A\/IIE","volume":"115","author":"Schneppenheim","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2026030916263022800_bib48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2012-01-405134","article-title":"Sequence and structure relationships within von Willebrand factor","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"issue":"133","key":"2026030916263022800_bib49","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1182\/blood-2018-10-876300","article-title":"The von Willebrand factor D\u2019D3 assembly and structural principles for factor VIII binding and concatemer biogenesis","volume":"14","author":"Dong","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2026030916263022800_bib50","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood.2021014729","article-title":"Structural basis of von Willebrand factor multimerization and tubular storage","volume":"139","author":"Zeng","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026030916263022800_bib51","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.jtha.2024.08.011","article-title":"Endothelial colony forming cells in the spotlight, insights into the pathophysiology of von Willebrand disease and rare bleeding disorders","volume":"22","author":"Laan","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026030916263022800_bib52","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jtha.2024.04.011","article-title":"Variant mapping using mass spectrometry\u2013based proteotyping as a diagnostic tool in von Willebrand disease","volume":"22","author":"Kreft","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2026030916263022800_bib53","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1182\/bloodadvances.2023010643","article-title":"Small interfering RNA\u2013mediated allele-selective silencing of von Willebrand factor in vitro and in vivo","volume":"7","author":"Jongejan","year":"2023","journal-title":"Blood Adv"},{"key":"2026030916263022800_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.thromres.2024.03.002","article-title":"Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor","volume":"236","author":"Jongejan","year":"2024","journal-title":"Thromb Res"},{"key":"2026030916263022800_bib55","unstructured":"National Library of Medicine\n          . The ALFA dataset: new aggregated allele frequency from dbGaP and dbSNP. Accessed 25 December 2025. https:\/\/ncbiinsights.ncbi.nlm.nih.gov\/2020\/03\/26\/alfa\/."},{"issue":"7571","key":"2026030916263022800_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"6096","key":"2026030916263022800_bib57","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"2026030916263022800_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.csbj.2019.11.006","article-title":"Computational approaches for effective CRISPR guide RNA design and evaluation","volume":"18","author":"Liu","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"issue":"8","key":"2026030916263022800_bib59","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.jtha.2025.04.024","article-title":"von Willebrand disease-specific defects and proteomic signatures in endothelial colony\u2013forming cells","volume":"23","author":"Laan","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026030916263022800_bib60","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.jtha.2024.03.018","article-title":"Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of endothelial colony forming cells","volume":"22","author":"Laan","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026030916263022800_bib61","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1111\/jth.14998","article-title":"Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease","volume":"18","author":"de Boer","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026030916263022800_bib62","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1038\/s41467-023-40655-6","article-title":"AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"issue":"3-4","key":"2026030916263022800_bib63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor","volume":"30","author":"Barbon","year":"2023","journal-title":"Gene Ther"},{"key":"2026030916263022800_bib64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-2660(10)69015-3","article-title":"Strategies for targeting tumors and tumor vasculature for cancer therapy","volume":"69","author":"Sreeramoju","year":"2010","journal-title":"Adv Genet"},{"issue":"9","key":"2026030916263022800_bib65","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2013Cas9 ribonucleoprotein","volume":"43","author":"Chen","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2026030916263022800_bib66","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V92.8.2791","article-title":"Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo","volume":"92","author":"Yamamoto","year":"1998","journal-title":"Blood"},{"issue":"9","key":"2026030916263022800_bib67","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/jth.15778","article-title":"SYMPHONY consortium: orchestrating personalized treatment for patients with bleeding disorders","volume":"20","author":"Cnossen","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1429\/2505508\/blooda_adv-2025-018760-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1429\/2505508\/blooda_adv-2025-018760-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:26:47Z","timestamp":1773088007000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1429\/557390\/Allele-selective-disruption-of-pathogenic-VWF"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018760","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,25]]}}}